Sugi Predict

Sugi Predict / Compounds / SCHEMBL1228429

SCHEMBL1228429

SCHEMBL1228429

c1ccc(OC2CCCNC2)cc1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 3/20 0.67
▸ CHRNA4 P43681 3/20 0.67
▸ HRH1 P35367 1/20 0.61
▸ ROCK1 Q13464 5/20 0.52
▸ SLC6A2 P23975 2/20 0.51
▸ HTR1A P08908 1/20 0.51
▸ IKBKB O14920 1/20 0.50
▸ CHUK O15111 1/20 0.50
▸ ROCK2 O75116 2/20 0.49
▸ PRKX P51817 1/20 0.49
▸ PRKCE Q02156 1/20 0.49
▸ PRKCD Q05655 1/20 0.49
▸ PRKD1 Q15139 1/20 0.49
▸ SLC6A4 P31645 2/20 0.49
▸ SLC6A3 Q01959 1/20 0.49
▸ KCNH2 Q12809 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17061888 1.00 CHRNB2 (0.67) CHRNB2CHRNA4HRH1ROCK1SLC6A2
SCHEMBL17593357 1.00 CHRNB2 (0.67) CHRNB2CHRNA4HRH1ROCK1SLC6A2
SCHEMBL19599782 0.95 CHRNB2 (0.60) CHRNB2CHRNA4HRH1ROCK1SLC6A2
SCHEMBL2523551 0.89 HRH1 (0.78) CHRNB2CHRNA4HRH1SLC6A2HTR1A
SCHEMBL14828522 0.89 HRH1 (0.78) CHRNB2CHRNA4HRH1SLC6A2HTR1A
SCHEMBL226349 0.89 HRH1 (0.78) CHRNB2CHRNA4HRH1SLC6A2HTR1A
Hydrochloric Acid SCHEMBL1769019 0.87 HRH1 (0.75) CHRNB2CHRNA4HRH1SLC6A2HTR1A
Hydrochloric Acid SCHEMBL796443 0.87 HRH1 (0.75) CHRNB2CHRNA4HRH1SLC6A2HTR1A
Hydrochloric Acid SCHEMBL795806 0.87 HRH1 (0.75) CHRNB2CHRNA4HRH1SLC6A2HTR1A
SCHEMBL29735458 0.85 HRH1 (0.85) CHRNB2CHRNA4HRH1ROCK1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676926-A1 BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS ThirtyFiveBio Limited (GB) 2026-01-14 — — EP disclosed
US-20250376452-A1 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof ENANTA PHARM INC (US) 2025-12-11 — — US disclosed
US-12384753-B2 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2025-08-12 — — US disclosed
WO-2024184650-A1 BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS. ThirtyFiveBio Limited (GB) 2024-09-12 — — WO disclosed
EP-4387603-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF Enanta Pharmaceuticals, Inc. (US) 2024-06-26 — — EP disclosed
CN-118103038-A 17 Beta-hydroxysteroid dehydrogenase 13 inhibitors and methods of use thereof 英安塔制药有限公司 2024-05-28 — — CN disclosed
EP-3596061-B1 COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER ARGONAUT THERAPEUTICS LTD (GB) 2023-09-06 — — EP disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 — — US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 — — EP disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 — — EP disclosed
WO-2008118758-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (GB) 2008-10-02 — — WO disclosed
US-20080176883-A1 Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone ABBVIE INC. 2008-07-24 — — US disclosed
US-5578582-A Methods of treating ischemia with C2, N6 -disubstituted adenosine derivatives NOVO NORDISK A/S (DK) 1996-11-26 — — US disclosed
US-5432164-A Anticonvulsants NOVO NORDISK A/S (DK) 1995-07-11 — — US disclosed
EP-0609375-A1 NOVEL 2,6-DISUBSTITUTED PURINE DERIVATIVES NOVO NORDISK A/S (DK) 1994-08-10 — — EP disclosed
WO-1993008206-A1 NOVEL 2,6-DISUBSTITUTED PURINE DERIVATIVES NOVO NORDISK A/S (DK) 1993-04-29 — — WO disclosed
US-4312876-A CENTRAL NERVOUS SYSTEM HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1982-01-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176883-A1 Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone MIF, CCL5, CCR2 CHRNB2 4471/4885CHRNA4 3990/4885HRH1 350/4885
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 CHRNB2 3245/4885CHRNA4 4211/4885HRH1 3349/4885
US-20250376452-A1 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof HSD17B1, HSD17B13, HSD17B3 CHRNB2 3245/4885CHRNA4 4211/4885HRH1 3349/4885
US-12384753-B2 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof HSD17B1, HSD17B13, HSD17B3 CHRNB2 3245/4885CHRNA4 4211/4885HRH1 3349/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 CHRNB2 469/4885CHRNA4 340/4885HRH1 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.